Literature DB >> 22694934

Vaccines against botulism.

Andrew P-A Karalewitz1, Joseph T Barbieri.   

Abstract

The clostridial neurotoxins (CNTs) are the most toxic proteins for humans and include botulinum neurotoxins (BoNT) and tetanus neurotoxin (TeNT). CNT neurotropism is based upon the preferred binding and entry into neurons and specific cleavage of neuronal SNARE proteins. While chemically inactive TeNT toxoid remains an effect vaccine, the current pentavalent vaccine against botulism is in limited supply. Recent advances have facilitated the development of the next generation of BoNT vaccines, utilizing non-catalytic full-length BoNT or a subunit vaccine composed of the receptor binding domain of BoNT as immunogens. This review describes the issues and progress towards the production of a vaccine against botulism that will be effective against natural BoNT variants.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694934     DOI: 10.1016/j.mib.2012.05.009

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  13 in total

1.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

2.  Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.

Authors:  Dan-Yang Shi; Bo-Yang Chen; Yun-Yun Mao; Guo Zhou; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Wei Zhou; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2018-12-04       Impact factor: 3.452

Review 3.  Botulinum neurotoxins: genetic, structural and mechanistic insights.

Authors:  Ornella Rossetto; Marco Pirazzini; Cesare Montecucco
Journal:  Nat Rev Microbiol       Date:  2014-06-30       Impact factor: 60.633

4.  Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.

Authors:  Zherong You; Hao Yang; Wenwen Xin; Lin Kang; Shan Gao; Junhong Wang; Tao Zhang; Jinglin Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

7.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

Review 8.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01

9.  Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza.

Authors:  Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Mingtao Zeng
Journal:  Front Immunol       Date:  2015-04-21       Impact factor: 7.561

10.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.